To enable widespread patient access to lifesaving cell and gene therapies, you need both superior biological performance and the benefits of digitally enabled automation to maximize your clinical and commercial impact. Explore IRO®See The Data Begin With Biology Ori has taken a biology-first approa...
LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) --Oribiotech Ltd.(Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces the first customer deliveries of the new IRO®platform, specifically designed to help address the curr...
CEO of Ori Biotech, describes how the current state of cell and gene therapies (CGTs) shows promising potential, particularly in curing cancer and rare diseases. These therapies are safe and effective, with evidence demonstrating their curative capability. However, their widespread adoption is hindere...
March 18, 2025 – Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO® platform. … Read more Patient Access Tracker Updated April 2025 – Ori has calculated the number of … Read more Ori Biotech Announces First Customer Deliveries of IRO to Leading CDMOs...